Citations

Showing 10 of 108094 citations.

Pushing Propofol and Gender Equity—Female Authorship in Anesthesia Publications
Pelkey, Melissa N. , Keim, Audrey , Folley, Tarrah, Broadfoot, Jourdan E. , Maloney, Jillian , Strand, Natalie , Misra, Lopa , Strand, Natalie H , Keim, Audrey Anne , Pelkey, Melissa N , Kraus, Molly B.

Mayo Clinic

Academic Medicine | October 26, 2022 | Volume: 97 | Issue: 11S | Pages: S174-S174

10.1097/acm.0000000000004811 Get It

Gender Disparities in Otolaryngology: A Case Report Reflecting Global Perspectives
Ali, Hawa M. , Lee, S.Y. , Jashek‐Ahmed, Farizeh , Seguya, Amina , Faucett, Erynne A. , Beck, Jenna Van , Stapleton, Emma , Peer, Shazia , Husain, Inna, Wiedermann, Joshua P. , Salano, Valerie , OHNS, Global, Faucett, Erynne A , Van Beck, Jenna , Wiedermann, Joshua , Peer, Shazia , OHNS, Global

Mayo Clinic

The Laryngoscope | October 26, 2022 | Volume: 133 | Issue: 3 | Pages: 547-551

10.1002/lary.30455 | PMID 36286081 Get It

ObjectivesTo explore the impact of female sex on the experiences of trainees and surgeons in otolaryngology from LMIC and HIC.MethodsThis study includes perspectives of five consultants and two resident physicians from the United States, United Kingdom, Uganda, Kenya and South Africa.ResultsSix themes emerged from these interviews. Overall, LMIC and HIC women shared similar experiences of microaggressions during patients, working along ancillary staff, related to pregnancy, imposter syndrome, difficulties during job search, and unique barriers as consultant.ConclusionsThe findings of this study highlight that gender disparities are present at all levels in Otolaryngology but can present differently depending on context. Laryngoscope, 133:547–551, 2023
Left Ventricular Cardiomyopathy in Mitral Valve Prolapse: Fact or Fiction?
Jost, Christina Attenhofer, Connolly, Heidi M. , Naegeli, Barbara, Faeh-Gunz, Anja, Scharf, Christoph , Candinas, R, Buechel, Emanuela Valsangiacomo, Franzen, Olaf, Jost, Christine H. Attenhofer , Greutmann, Matthias , Buechel, Emanuela R. Valsangiacomo , Weber, Roland W. , Binggeli, Christian , Medeiros‐Domingo, Argelia

Mayo Clinic

EMJ Cardiology | October 26, 2022 | Volume: No volume available | Issue: No issue available | Pages: 30-37

10.33590/emjcardiol/10313096 Get It

In most patients with mitral valve prolapse (MVP) without severe mitral regurgitation (MR), left ventricular (LV) function is preserved. There are, however, patients with MVP who have unexplained LV dilatation and/or decreased LV function. An association between MVP and sudden cardiac death has also been reported. LV size and function may be affected by the type of MVP, severity of regurgitation, and cause of MVP (myxomatous degeneration versus fibroelastic deficiency). There is increasing evidence suggesting an intrinsic cardiomyopathy associated with MVP. The cardiomyopathy associated with MVP can also affect the right ventricle (RV). Although the impact on ventricular dimensions and function are usually subtle, these abnormalities can affect clinical and echocardiographic estimation of the severity of MR and may thus have an impact on therapeutic decisions. Particularly in patients with the most extreme forms of MVP (Barlow disease), and in patients with Marfan syndrome or other connective tissue disorders, a cardiomyopathy affecting the LV and RV may thus occur occasionally. A better understanding of LV impairment associated with MVP is important for risk assessment and clinical decision-making.
Narrative review of peripheral nerve blocks for the management of headache
Stern, Jennifer I. , Chiang, Chia‐Chun , Robertson, Carrie E. , Chiang, Chia-Chun , Robertson, Carrie E , Kissoon, Narayan

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 26, 2022 | Volume: 62 | Issue: 9 | Pages: 1077-1092

10.1111/head.14385 | PMID 36286600 Get It

Abstract Objective To provide an overview of the current available literature on peripheral nerve blocks for the management of migraine and other headache disorders in adults. Background Peripheral nerve blocks have been commonly performed in the headache practice for migraine, cluster headache, occipital neuralgia, and other headache disorders, despite a paucity of evidence supporting their use historically. In the past decade, there has been an effort to explore the efficacy and safety of peripheral nerve blocks for the management of headache, with the greatest interest centered around greater occipital blocks. Design We performed a search in PubMed using key words including “occipital nerve blocks,” “peripheral nerve blocks,” “occipital nerve,” “migraine,” “cluster headache,” and “neuralgia.” We reviewed the randomized controlled trials (RCTs), observational studies, and case series, and summarized the anatomy, techniques, and the evidence for the use of peripheral nerve blocks in different headache disorders, with particular focus on available RCTs. Case reports were included for a detail review of adverse events. Results Of 12 RCTs examining the use of greater occipital nerve blocks for migraine, all but one demonstrate efficacy with reduction in headache frequency, intensity, and/or duration compared to placebo. Studies have not demonstrated a difference in clinical outcomes with the use of corticosteroids for nerve blocks compared to blocks with local anesthetic in the treatment of migraine. There are two RCTs supporting the use of greater occipital blockade for cluster headache, both showing benefit of suboccipitally injected corticosteroid. One RCT suggests benefit of greater occipital nerve blocks for cervicogenic headache. Observational studies and case series/reports show that greater occipital nerve block may be effective in prolonged migraine aura, status migrainosus, post‐dural puncture headache, and occipital neuralgia. Overall, peripheral nerve blocks are well tolerated. Serious side effects are rare but have been reported, including acute cerebellar syndrome and infection. Conclusions Peripheral nerve blocks, especially occipital nerve blocks, are a viable treatment option for migraine and may be helpful in cluster headache as a transitional therapy or rescue therapy. Additional prospective studies are needed to investigate the efficacy and safety of occipital nerve blocks for long‐term migraine prevention, as well as for other headache disorders, such as occipital neuralgia.
Trilayered Hydrogel Scaffold for Vocal Fold Tissue Engineering
Tindell, R. Kevin, McPhail, Michael, Myers, Cheryl , Neubauer, Juergen, Hintze, Justin M. , Holloway, Julianne L. , McPhail, Michael J., Myers, Cheryl E, Holloway, Julianne L , Myers, Cheryl E , Hintze, Justin , Lott, David G.

Mayo Clinic

Biomacromolecules | October 26, 2022 | Volume: 23 | Issue: 11 | Pages: 4469-4480

10.1021/acs.biomac.1c01149 | PMID 36286235 Get It

H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes
Day, Charles , Hinchcliffe, Edward H. , Day, Charles A , Robinson, James

Mayo Clinic

Cells | October 26, 2022 | Volume: 11 | Issue: 21 | Pages: 3376

10.3390/cells11213376 | PMID 36359771 Get It

Histone post-translational modifications modulate gene expression through epigenetic gene regulation. The core histone H3 family members, H3.1, H3.2, and H3.3, play a central role in epigenetics. H3 histones can acquire many post-translational modifications, including the trimethylation of H3K27 (H3K27me3), which represses transcription. Triple methylation of H3K27 is performed by the histone methyltransferase Enhancer of Zeste Homologue 2 (EZH2), a component of the Polycomb Repressive Complex 2. Both global increases and decreases in H3K27me3 have been implicated in a wide range of cancer types. Here, we explore how opposing changes in H3K27me3 contribute to cancer by highlighting its role in two vastly different cancer types; (1) a form of glioma known as diffuse midline glioma H3K27-altered and (2) epithelial ovarian cancer. These two cancers vary widely in the age of onset, sex, associated mutations, and cell and organ type. However, both diffuse midline glioma and ovarian cancer have dysregulation of H3K27 methylation, triggering changes to the cancer cell transcriptome. In diffuse midline glioma, the loss of H3K27 methylation is a primary driving factor in tumorigenesis that promotes glial cell stemness and silences tumor suppressor genes. Conversely, hypermethylation of H3K27 occurs in late-stage epithelial ovarian cancer, which promotes tumor vascularization and tumor cell migration. By using each cancer type as a case study, this review emphasizes the importance of H3K27me3 in cancer while demonstrating that the mechanisms of histone H3 modification and subsequent gene expression changes are not a one-size-fits-all across cancer types.
All-Soft Tissue Quadriceps Tendon Autograft in Revision Anterior Cruciate Ligament Reconstruction in Athletes: Comparison to Bone-Patellar Tendon-Bone Autograft With at Least a 2-Year Follow-up
Brinkman, Joseph C. , Moore, Michael L., Economopoulos, Kostas J. , Tummala, Sailesh V , Tummala, Sailesh V. , Moore, Michael L.

Mayo Clinic

The American Journal of Sports Medicine | October 26, 2022 | Volume: 50 | Issue: 14 | Pages: 3770-3777

10.1177/03635465221126523 | PMID 36285655 Get It

Background: Revision anterior cruciate ligament (ACL) reconstruction is being performed at an increasing rate. Previous literature has suggested that autograft ACL reconstruction is a better option than allograft in revision surgery, although the optimal autograft choice remains unknown. The all–soft tissue quadriceps tendon (ASTQT) autograft has been found to be an effective option for primary ACL reconstruction. However, few studies have evaluated ASTQT autograft in revision ACL reconstruction. Purpose/Hypothesis: The purpose of this study was to evaluate the ASTQT autograft in revision ACL reconstruction in athletes compared with bone–patellar tendon–bone (BTB) autograft. We hypothesized that the ASTQT autograft would lead to similar return to play, time to return to play, retear rate, and patient-reported outcomes compared with BTB autograft. Study Design: Cohort study; Level of evidence, 3. Methods: A retrospective study was performed on all athletes undergoing revision ACL reconstruction between August 2013 and December 2019 at a single institution. Patients participating in high school or college athletics undergoing first-time revision with either ASTQT or BTB autograft with ≥2 years of follow-up were included. Demographic variables, complications, return to sports, and outcome scores including the International Knee Documentation Committee (IKDC) and Lysholm were collected and compared between the 2 cohorts. Results: A total of 58 revision ACL reconstructions were included, with 32 in the ASTQT cohort and 26 in the BTB cohort. Return to sports at the same level occurred in 62.5% of the ASTQT group and 53.8% of the BTB group. The ASTQT group returned to sports significantly faster than the BTB group (8.9 vs 10.3 months; P = .020). There was no difference in retear rates (3.1%, ASTQT; 7.7%, BTB) or other complications between the 2 groups. The IKDC scores were significantly higher at the 6- and 12-month follow-up for the ASTQT autograft group compared with the BTB group (6 months: ASTQT, 71.3; BTB, 61.7, P = .001; 12 months: ASTQT, 82.7; BTB, 78.6; P = .021). Lysholm scores were also greater in the ASTQT cohort at these time points (6 months: ASTQT, 75.1; BTB, 63.6; P < .001; 12 months: ASTQT, 82.0; BTB, 74.5; P < .001). However, IKDC and Lysholm scores were similar between both groups at final follow-up (IKDC: ASTQT, 82.9; BTB, 81.7; P = .344; Lysholm: ASTQT, 83.0; BTB, 81.0; P = .104) There was no significant clinical difference in the absolute difference in scores or rate of achieving clinical thresholds between the 2 cohorts. Conclusion: ASTQT autograft for revision ACL in athletes has similar outcomes compared with BTB autograft. However, the ASTQT may possibly afford quicker return to sports and better early improvements in patient-reported outcomes that normalize by 1 year. The soft tissue quadriceps autograft should be considered a viable graft option in revision ACL reconstruction in athletes.
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi‐institutional retrospective cohort s
Rose, Kyle , Narang, Gopal , Labatte, Craig, Dumitrascu, Catalina I. , Campagna, Justin, Manley, Brandon J., Spiess, Phillippe E., Li, Roger , Adibi, Mehrad , Sexton, Wade J. , Humphreys, Mitchell R. , Manley, Brandon J. , Rose, Kyle M , Li, Roger , Adibi, Mehrad , Manley, Brandon J , Rosen, Geoffrey H. , Yu, Alice , Murray, Katie S.

Mayo Clinic

BJU International | October 26, 2022 | Volume: 131 | Issue: 4 | Pages: 471-476

10.1111/bju.15925 | PMID 36285629 Get It

Objectives To assess the safety profile of antegrade mitomycin gel instillation through a percutaneous nephrostomy tube (PCNT) for upper tract urothelial carcinoma (UTUC) with the aim of decreasing morbidity associated with therapy. Patients and Methods Patients undergoing antegrade administration of mitomycin gel via PCNT were retrospectively included for analysis from four tertiary referral centres between 2020 and 2022. The primary outcome was safety profile, as graded by Common Terminology Criteria for Adverse Events (v5.0). Post‐therapy disease burden was assessed by primary disease evaluation (PDE) via ureteroscopy. Results Thirty‐two patients received at least one dose of mitomycin gel via PCNT for UTUC, 29 of whom completed induction and underwent PDE. Thirteen patients (41%) had residual tumour present prior to induction therapy. At a median of 15.0 months following first dose of induction therapy, ureteric stenosis occurred in three patients (9%), all of whom were treated without later recurrence or chronic stenosis. Other adverse events included fatigue (27%), flank pain (19%), urinary tract infection (12%), sepsis (8%) and haematuria (8%). No patients had impaired renal function during follow‐up and there were no treatment‐related deaths. Seventeen patients (59%) had no evidence of disease at PDE and have not experienced recurrence at a median follow‐up of 13.0 months post induction. Conclusions Administration of mitomycin gel via a PCNT offers a low rate of ureteric stenosis, demonstrates a favourable safety profile, and is administered without general anaesthesia.
Early neurological deterioration as a predictor of outcomes after endovascular thrombectomy for stroke: A systematic review and meta-analysis
Kobeissi, Hassan , Ghozy, Sherief , Seymour, Trey , Bilgin, Cem , Kadirvel, Ramanathan , Kallmes, David F. , Ghozy, Sherief , Seymour, Trey J , Kobeissi, Hassan , Bilgin, Cem

Mayo Clinic

Interventional Neuroradiology | October 26, 2022 | Volume: 30 | Issue: 4 | Pages: 451-457

10.1177/15910199221135289 | PMID 36285526 Get It

Background Early neurological deterioration (END) is a potential predictor for 90-day outcomes following mechanical thrombectomy for acute ischemic stroke (AIS). We performed a systematic review and meta-analysis to better understand whether END can be used as a surrogate for long-term outcomes. Methods Following the PRISMA guidelines, a systematic literature review of the English language literature was conducted using PubMed, MEDLINE, and Embase. END definition was cataloged for each included study. Outcomes of interest included 90-day modified Rankin Scale (mRS) 0–2, symptomatic intracranial hemorrhage (sICH), mortality, and thrombolysis in cerebral infarction (TICI) 2b-3. We calculated pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CI) for all definitions of END. Results We included seven studies with 2992 patients in our analysis. There was a significant, inverse association with END and mRS 0–2 rates (OR = 0.15; 95% CI = 0.08–0.29; P-value< 0.001). Moreover, END was a significant predictor of increased odds for reported sICH rates (OR = 16.37; 95% CI = 7.66–34.99; P-value< 0.001). Furthermore, there was a significant association between END and increase in mortality rates (OR = 6.79; 95% CI = 2.62–17.62; P-value< 0.001). There was no significant association between END and rates of TICI 2b-3 (OR = 0.53; 95% CI = 0.27–1.05; p = 0.069). Conclusions Broadly defined, END holds value as a potential predictor of rates of mRS 0–2 at 90 days and is associated with higher rates of mortality and sICH, but had no correlation with TICI 2b-3.
Noncanonical JAK1/STAT3 interactions with TGF-β modulate myofibroblast transdifferentiation and fibrosis
Wang, Faping , Wang, Shaohua , Zhang, Chujie , Tian, Xue, Zhou, Yongfang , Xuan, Weixia , Matteson, Eric L. , Luo, Fengming, Tschumperlin, Daniel J. , Vassallo, Robert , Tschumperlin, Daniel J , Vassallo, Robert , Tian, Xue

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | October 25, 2022 | Volume: 323 | Issue: 6 | Pages: L698-L714

10.1152/ajplung.00428.2021 | PMID 36283961 Get It

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited survival. Janus kinases (JAKs), tyrosine kinases that transduce cytokine-mediated signals, are known to be involved, but their specific roles in lung fibrosis are not well defined. In this study, the interactions between JAK1/signal transducers and activators of transcription (STAT)3 signaling and transforming growth factor-beta (TGF-β)-induced fibroblast responses were investigated using both pharmacological and siRNA approaches in human normal and IPF-derived lung fibroblasts. We found that JAK1 directly interacts with the TGF-β receptor I subunit (TβRI), and silencing JAK1 promotes myofibroblast transdifferentiation. However, the suppression of JAK1 signaling in vitro and in vivo using an inhibitor (upadacitinib) did not alter lung fibroblast activation or fibrosis development. STAT3 was constitutively active in cultured primary lung fibroblasts; this STAT3 activation required JAK1 and repressed myofibroblast transdifferentiation. Loss of phosphorylated STAT3 following transcriptional JAK1 silencing promoted myofibroblast transdifferentiation. In contrast, transcriptional silencing of unphosphorylated STAT3 suppressed TGF-β signaling, decreased SMAD3 activation, and reduced myofibroblast transdifferentiation and ECM production. Taken together, these observations support a role for JAK1/STAT3 as a direct regulator of TGF-β signaling in lung fibroblasts. Modulation of JAK1/STAT3 signaling in lung fibroblasts represents a noncanonical approach to regulating TGF-β-induced fibrosis and suggests the potential for a novel approach to treat pulmonary fibrosis.